In the Alzheimer’s disease pathway which contained 30 MFS-AD-treating targets, more targets were related to protease and serine/threonine–protein kinase, including two core targets, AKT1 and MAPK3 (Figure 6C). This evidence concerns the gene WEE1 and early-onset autosomal dominant Alzheimer disease.